(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
Pedal Power: Divulging Well known Bike Brands for Each Cyclist- Step by step instructions to Recognize the Distinction Between Lab Jewels and Precious stone Simulants
- Why screening for the deadliest cancer in the U.S. misses most cases
- Instructions to Decide whether a Fender bender Legal counselor is Required for Your Particular Case
- the 6 Shrewd Beds for seniors: A Complete Survey
- Turkey's Erdogan denounces Israel-Greece-Cyprus trilateral summit, affirms support for Gaza
- I'm a hypnotherapist who helps day traders who are losing money. Here's why I think hypnosis works.
- 10 Demonstrated Tips to Dominate Video Altering on Your Cell phone in 2023
- 'Zootopia 2' movie reviews: A heartwarming, hysterical and earnest 'ode to community'
